339 related articles for article (PubMed ID: 36650006)
1. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.
Tillett W; Ogdie A; Passey A; Gorecki P
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36650006
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
3. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
[TBL] [Abstract][Full Text] [Related]
4. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
Haugeberg G; Michelsen B; Kavanaugh A
RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
[TBL] [Abstract][Full Text] [Related]
5. Clinical Burden of Concomitant Joint Disease in Psoriasis: A US-Linked Claims and Electronic Health Records Database Analysis.
Skornicki M; Prince P; Suruki R; Lee E; Louder A
Adv Ther; 2021 May; 38(5):2458-2471. PubMed ID: 33818686
[TBL] [Abstract][Full Text] [Related]
6. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
9. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
[TBL] [Abstract][Full Text] [Related]
13. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
14. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.
Ahmed N; Prior JA; Chen Y; Hayward R; Mallen CD; Hider SL
Clin Rheumatol; 2016 Dec; 35(12):3069-3073. PubMed ID: 27485152
[TBL] [Abstract][Full Text] [Related]
17. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
18. Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists.
Wu CY; Chang YT; Juan CK; Shen JL; Lin YP; Shieh JJ; Liu HN; Chen YJ
Medicine (Baltimore); 2016 May; 95(22):e3816. PubMed ID: 27258525
[TBL] [Abstract][Full Text] [Related]
19. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study.
Ballegaard C; Skougaard M; Guldberg-Møller J; Nissen CV; Amris K; Jørgensen TS; Dreyer L; Kristensen LE
Rheumatology (Oxford); 2021 Jul; 60(7):3289-3300. PubMed ID: 33325531
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
